Notice: Undefined property: stdClass::$name in /home/financial-trends.com/wp-content/plugins/wp-change-custom-post-slug/wp-change-custom-post-slugs.php on line 140

Notice: register_post_type was called incorrectly. Post type names must be between 1 and 20 characters in length. Please see Debugging in WordPress for more information. (This message was added in version 4.2.0.) in /home/financial-trends.com/wp-includes/functions.php on line 5313

Notice: Constant WP_MEMORY_LIMIT already defined in /home/financial-trends.com/wp-config.php on line 126
Valneva stock: The next top news comes to nothing! - Financial Trends

Valneva stock: The next top news comes to nothing!

The stock of the French-Austrian vaccine manufacturer Valneva got off to a buoyant start in trading on Monday morning. In the first minutes of trading, prices gained a good 4 percent to mark a high of 9.650 euros. The company had previously published positive homologous and heterologous booster results for the Covid-19 vaccine VLA2001.

Based on the clinical results, Valneva concludes that the inactivated vaccine is capable of boosting neutralizing antibody titers to what is considered a highly effective rate of 90 percent. This is true for both basic immunization with Valneva’s inactivated inactivated vaccine and with AstraZeneca’s Covid-19 vaccine, he said.

Where do we go from here?

In parallel, another heterologous booster study is ongoing to determine the efficacy of a booster vaccination in the case of basic immunization with an mRNA vaccine and in the case of natural infection. Only if these data are available in the fourth quarter and are positive, VLA2001 could receive regulatory approval for heterologous booster vaccination.

Just a week ago, the World Health Organization (WHO) issued an official recommendation for the Valneva vaccine in adults. Now, this recommendation has been extended to include the indication that the vaccine can also be considered as a booster vaccination in case of a first vaccination with the AstraZeneca drug.

The stock market is not very impressed

But neither a week ago nor on Monday does the news, which is in itself very positive, leave a lasting impression. In a weak overall market, the Valneva stock even goes slightly lower out of trading on Monday. This shows that investors no longer see too much potential in the Covid 19 vaccine program following the cancellation of supply contracts by the EU and the UK. After all, the market is already well supplied by Moderna and BioNTech/Pfizer funds.

Major impulses for the Valneva stock lurk here

In contrast, other vaccines within the Valneva pipeline could provide strong impetus. With the Lyme disease vaccine VLA15 and the chikungunya vaccine VLA1553, the French-Austrian company still has two hopefuls with great sales potential in the race. In my opinion, their development successes are still far too little appreciated on the stock market. At the current level, an investment therefore offers a good risk-reward ratio.